Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine therapy--current benefits and limitations.

Robert I Nicholson1, Stephen R Johnston

  • 1Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK. nicholsonri@cardiff.ac.uk

Breast Cancer Research and Treatment
|October 26, 2005
PubMed
Summary

Endocrine therapy for estrogen receptor-positive breast cancer faces resistance. New agents like fulvestrant and combination therapies targeting estrogen receptor (ER) and growth factor pathways may overcome resistance and improve treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Breast cancer research : BCR·2025
Same author

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

NPJ breast cancer·2022
Same author

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.

NPJ breast cancer·2020
Same author

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.

Oncogene·2020
Same author

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Breast cancer research : BCR·2020
Same author

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Breast cancer research : BCR·2019

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Endocrine therapy is a primary treatment for postmenopausal women with estrogen receptor (ER)-positive breast cancer.
  • Tamoxifen, a long-standing endocrine therapy, presents tolerability issues and risks, with acquired resistance being a significant clinical challenge.
  • Estrogen receptor (ER) activation can occur through both estrogen-dependent and -independent pathways, involving cross-talk with growth factor signaling, which contributes to endocrine resistance.

Purpose of the Study:

  • To review current endocrine therapy approaches for ER-positive breast cancer.
  • To explore the mechanisms of de novo and acquired resistance to endocrine therapy.
  • To discuss novel therapeutic strategies, including fulvestrant and combination therapies, for overcoming endocrine resistance.

Related Experiment Videos

Main Methods:

  • Review of existing literature on endocrine therapy for breast cancer.
  • Analysis of molecular mechanisms underlying ER activation and resistance.
  • Evaluation of novel agents targeting ER and growth factor signaling pathways.

Main Results:

  • Acquired resistance to endocrine therapy is often mediated by cross-talk between ER and growth factor signaling pathways.
  • Fulvestrant, an ER antagonist, induces ER degradation and abrogates ER signaling, potentially preventing or delaying resistance.
  • Combination therapies targeting both ER and growth factor pathways show promise in delaying endocrine resistance.

Conclusions:

  • Understanding the complex signaling pathways involved in ER activation is crucial for developing effective breast cancer treatments.
  • Fulvestrant represents a promising therapeutic option for endocrine-resistant breast cancer.
  • Combining antiestrogenic drugs with growth factor signaling inhibitors may offer a strategy to overcome endocrine resistance and enhance treatment efficacy.